



Analysing Chem/Bio-Markers in Saliva using a Portable Optical Detection Platform

Simon Coleman

Andrew Kavanagh, Dylan Orpen, Jung Ho Kim, King Tong Lau and Dermot Diamond

CLARITY: Centre for Sensor Web Technologies, National Centre for Sensor Research, Dublin City University, Dublin 9, Ireland

Overview

- ***Treatment and monitoring of Bipolar Disorder***
 - *Lithium therapy for mood stabilisation*
 - *Non-invasive sampling of patient*
- ***Chemo/Bio-markers for Bipolar patient monitoring***
 - *Fluorescent detection of Lithium*
 - *Colourimetric determination of α -amylase*
- ***Portable analysis of Bipolar disorder using multi-analyte platform***
- ***Detection of Chemo/Bio-markers using mobile platform***
- ***Conclusions and future applications***

Treatment and monitoring of Bipolar Disorder

Lithium treatment for mood stabilisation

- Current treatment of Bipolar disorder involves administration of Lithium in the form of lithium carbonate tablets.
- Typical serum (blood) levels range between $0.6 - 1.3\text{mmol}^1$ with toxic levels above 1.5mmol^1

➔ **narrow therapeutic/toxic range**

Two issues from current methods of monitoring dosage:

1. Blood typically drawn **ONCE** weekly to determine lithium levels in patient.
 - Risk of **overdose/intoxication** event being missed by infrequent monitoring
2. Invasive nature of blood drawing procedure.
 - Discomfort associated with blood sampling

¹ R. Regenthal et al, J. Clin. Monit., 1999, 15, 529-544

Bipolar Disorder

Non-invasive sampling of patient


- *Invasive nature of drawing blood limits number of samples and decreases patient compliance.*
- *Interest in alternatives to Blood analysis sought for conditions requiring frequent analysis such as Diabetes.*
- *Saliva chosen due to ease of accessibility, low sample preparation requirements and minimal invasiveness.*



Bio/Chemo-markers for Bipolar Patient monitoring


Chemical marker: Lithium

- Uncommon element in body resulting in minimal interference due to alternate sources of lithium.
- Readily found in bodily fluids during treatment; urine, saliva, blood and sweat. Typically found to be in higher concentration in saliva than blood



Biomarker: α -amylase

- Present in blood (Pancreatic) and saliva (salivary)
- Salivary α -amylase found to exhibit sensitivity to stress.
- Proposed use as stress monitor in conjunction with other methods of mood analysis (psychiatric assessment, vocal pattern analysis) .




Lithium (top): http://www.sciencephoto.com/image/111204/530wm/C0046993-Lithium_Carbonate-SPL.jpg <accessed 14/06/12>

Amylase (bottom): <http://www.salimetrics.com/my-spit-research/analytes/a-amylase.php> <accessed 11/06/12>


Fluorescent Detection of Lithium

- Highly sensitive method using 'dark background' and lithium specific probe dye.
- 1,4-Dihydroxyanthraquinone (Quinizarin) found to preferentially complex with Lithium
- Complex absorption at 605nm and corresponding emission at 624nm




Quinizarin dye and Lithium complex formation


Fluorescent Detection of Lithium



Excitation spectrum of 1mM Quinizarin-lithium complex




Emission spectrum of 1mM Quinizarin-lithium complex




Colorimetric determination of α -amylase

- Exploitation of α -amylase enzymatic break down of starch.
- Water insoluble starch polymer with attached blue dye is added to aqueous saliva sample.
- As the starch is broken down, the dye is released into the water resulting in colour change.
- Measurement of absorption at 620nm allows for the determination of amylase concentration in saliva.





Colour change in α -amylase concentrations in response to stress

Colorimetric determination of α -amylase





Characteristic absorption spectra of released blue dye following breakdown of starch polymer backbone.





Absorption changes related to varying levels of amylase present in saliva throughout a day (healthy individual)

Portable analysis of Bipolar disorder using multi-analyte platform





Portable analysis of Bipolar disorder using multi-analyte platform

- **Wireless microcontroller (Wixel[®]) with dual LED system and individual photodiode detectors optimized for each target marker.**
- **Automated Software programme:**
 - **'li' (lithium) and 'aa' (α -amylase) commands initiate custom measurement routine.**
 - **180s settling time hard coded to device for lithium analysis.**
 - **20 individual measurements printed to screen**
 - **Device calculates average and prints to screen.**




Portable analysis of Bipolar disorder using multi-analyte platform

Fluorescence:
Absorbance detection
Exc: 605nm
Emission detection
Abs: 620nm



Determination of Chemo/Bio-markers using mobile platform

- Standard addition technique to determination of lithium levels:
 - Increasing addition of stock solution containing lithium of known concentration added to saliva sample containing unknown lithium concentration.
 - Validation versus standard method (ICP-AES)




<i>sample</i>	<i>concentration (mM)</i>
Known saliva concentration	1.00
Portable platform measurement	1.06
ICP-AES measurement	0.93
standard deviation	0.09



Standard addition curve for the determination of unknown saliva lithium concentration

Determination of Chemo/Bio-markers using mobile platform

- Calibration curve for determination of α -amylase:
 - Calibration curve constructed using human amylase standard
 - Device optimised for determination of alpha-amylase levels within specific range (0.1 U/mL – 1.2 U/mL)
 - Clinical trials in progress.



Calibration curve of amylase using portable platform



(a) UV-Vis spectra of amylase standards. (b) Calibration curve for validation using UV-Vis

Conclusions and future applications

- *Use of Non-invasive sample for **increased frequency of patient monitoring** .*
- *Reliable Portable optical detection of both chemical and biological markers for eventual **Reduction in requirement for hospital visits** with patients able to determine levels at home.*
- ***Customisable** nature of device allows for the potential of tailoring the system (LEDs and detectors) to alternative targets that can be detected optically allowing for use with other disorders.*

Acknowledgements



- **Prof. Dermot Diamond, CLARITY: Centre for Sensor Web Technologies, Dublin City University**
- **Dr. Claudio Gentili, Department of Psychiatry, S. Chiara Hospital, Pisa**
- **European Union for PSYCHE FP7 project funding**